Announcements Trials
Browse Landscape

Phase

Phase 3 1

Status

Recruiting 1

Sponsor Class

NIH 1

Study Type

Interventional 1

Sponsor

Cancer Type

Lymphoid 1

Conditions

Lymphoma 35Small Cell Lung Carcinoma 34Leukemia 34Lung Neoplasms 25Leukemia, Myeloid, Acute 25Precursor Cell Lymphoblastic Leukemia-Lymphoma 24Lymphoma, Large B-Cell, Diffuse 19Neuroblastoma 15Lymphoma, Non-Hodgkin 15Carcinoma, Non-Small-Cell Lung 14Leukemia, Erythroblastic, Acute 13Hodgkin Disease 13Leukemia, Myelomonocytic, Acute 12Leukemia, Monocytic, Acute 12Leukemia, Megakaryoblastic, Acute 12Sarcoma 11Lymphoma, Follicular 10Burkitt Lymphoma 10Lymphoma, Large-Cell, Immunoblastic 9Testicular Neoplasms 7Teratoma 7Myelodysplastic Syndromes 7Congenital Abnormalities 7Multiple Myeloma 6Endodermal Sinus Tumor 6Anemia, Refractory, with Excess of Blasts 6Testicular Germ Cell Tumor 5Ovarian Neoplasms 5Neuroectodermal Tumors, Primitive, Peripheral 5Central Nervous System Neoplasms 5

Interventions

prednylidene 1etoposide phosphate 1deltacortene 1Vincristine 1Vinblastine 1Specimen Handling 1Procarbazine 1Prednisone 1Prednisolone 1Nivolumab 1Methylprednisolone 1Magnetic Resonance Spectroscopy 1Fluorodeoxyglucose F18 1Etoposide 1Doxorubicin 1Dacarbazine 1Cyclophosphamide 1Brentuximab Vedotin 1Bleomycin 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Phase 3 × Lugano Classification Limited Stage Hodgkin Lymphoma AJCC v8 × Etoposide × Clear all
NCT05675410 2026-06-03

A Study to Compare Standard Therapy to Treat Hodgkin Lymphoma to the Use of Two Drugs, Brentuximab Vedotin and Nivolumab

National Cancer Institute (NCI)

Phase 3 Recruiting
1,875 enrolled
Lymphoid

Lugano Classification Limited Stage Hodgkin Lymphoma AJCC v8

Data powered by HemOnc (CC BY 4.0) Colophon âš¡